drugset / Trial / NCT07649941

A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood

NCT07649941

Phase 1 Recruiting 16 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of a moderate CYP 3A inducer bosentan on the pharmacokinetics of zongertinib.

Timeline

Start
2026-06-22
Primary completion
2026-08-19
Completion
2026-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified
Subject Zongertinib Small molecule

Indications

No indication recorded.